Provider review
Renlo Health review: it cites the right trial, names the journal, and calls the number an average
Under each of Renlo's weight-loss charts is a single line: "Average results in the STEP 1 trial, New England Journal of Medicine." The tirzepatide page says the same about SURMOUNT-1. Right trial, right journal, right molecule — and the word "average" doing exactly the work it should. That sounds like a low bar. It isn't. Most sellers we grade quote a percentage from nowhere, and one in this same batch puts a sixteen-month result at month six. Renlo publishes no timeline at all, which leaves it nothing to get wrong.
Cites the right trial for the right molecule, calls the figure an average, and publishes no timeline to get wrong.
Worth trusting if
- You want a seller that names the trial and the journal its numbers come from
- You want the figure labeled an average rather than sold to you as a schedule
- You want the price to hold as your dose climbs, which Renlo promises and prices
Be skeptical if
- You want to know which pharmacy makes your medication, which this site does not say
- You are weighing its comparison table against rivals, because it names none of them
- You want a trial behind its NAD+ or glutathione products, which carry a benefit line and nothing else
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.renlohealth.com. A link is not a recommendation to take anything.
Provenance
What Renlo Health actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection — $199 a month, billed monthly, flat at every dose.
- Compounded tirzepatide injection — $269 a month, on the same terms as the semaglutide plan.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Molecules with human evidence
For the use they are sold for, out of 2 products reviewed here. The evidence belongs to the molecule, not to Renlo Health.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Renlo Health’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded semaglutide injectionSemaglutide · Compounded (503A)Claim matches the trials
“Average results in the STEP 1 trial, New England Journal of Medicine. A once-weekly compounded semaglutide injection, prescribed by a provider as part of a personalized treatment plan. Same price at every dose.”
Read on the Renlo Health site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in 1,961 adults with a body-mass index of 30 or above, or 27 or above with a weight-related condition. Reported a mean weight reduction of about 15% on semaglutide 2.4 mg against about 2% on placebo.
Renlo names the trial, names the journal, and calls the figure an average — three things that go wrong constantly elsewhere and go right here. The attribution is also correctly scoped: the STEP 1 line appears on the semaglutide page and the SURMOUNT-1 line on the tirzepatide page, rather than one citation being stretched across both. What Renlo does not do is turn the trial into a schedule. There is no month-by-month curve, no promised milestone and no maintenance percentage anywhere on the site, which is the step where sellers usually lose the thread. One caveat that applies to every compounded product and not to Renlo in particular: STEP 1 tested the manufacturer's approved semaglutide, not a compounded preparation, and no trial has compared the two.1
Compounded tirzepatide injectionTirzepatide · Compounded (503A)Claim matches the trials
“Average results in the SURMOUNT-1 trial, New England Journal of Medicine. A once-weekly compounded tirzepatide injection, prescribed by a provider as part of a personalized treatment plan.”
Read on the Renlo Health site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks in 2,539 adults with obesity or overweight and no diabetes, at 5, 10 and 15 mg once weekly. Reported a mean reduction of roughly 20% at the top dose.
Same discipline as the semaglutide page, and the citation is matched to the right molecule rather than borrowed from the other one. The figure is labeled an average, no timeline is attached to it, and no maintenance claim is made. As with every compounded product on this site, the trial tested the manufacturer's approved tirzepatide rather than a compounded version, and nothing published compares the two.2
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named and no compounding tier is published — nothing on the site says whether the medication is made to order under a prescription or dispensed ready-made. The prescribing side is not named at the individual level either: "a licensed provider" recurs throughout, with no clinician, medical director or advisory panel identified. What Renlo does publish is a LegitScript certification, and it is real and belongs to this domain: the certificate image loads for renlohealth.com and an invented certificate number returns an error in the same check. That proves a certificate was issued to this site. It is not an audit of anything that arrives in the box.
Read on the Renlo Health site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, potency, purity or sterility result appears anywhere on the site. The one figure Renlo publishes without a source is commercial rather than clinical: a table showing "most GLP-1 providers" charging more as the dose climbs, naming none of them. Its own footnote hedges that as illustrative of typical pricing in the category, which is more than most unsourced comparisons carry. On the clinical side, the site's restraint is the notable thing — a trial citation under each chart, an average rather than a promise, and no month-by-month schedule built out of either.
Read on the Renlo Health site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
Renlo publishes no list of states and claims no nationwide coverage, on its homepage, its product pages or its FAQ, checked on September 13, 2026. Coverage is decided at the free assessment, which is where the site sends every eligibility question.
Read the full licensing claim
The operating company appears only in a copyright line — Renlo Health LLC — with no street address, state of incorporation or governing-law clause anywhere on the site. No clinician is named.
Read on the Renlo Health site, September 2026.
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- It names the trial behind each figure — STEP 1 for semaglutide, SURMOUNT-1 for tirzepatide — and the journal.
- Each citation sits on the right molecule's page, rather than one trial being stretched across both drugs.
- It calls the number an average, which is what it is.
Show 4 more
- It publishes no month-by-month timeline, so it never reshapes a trial result into a promise.
- Its LegitScript certification is real and belongs to this domain.
- Its four-month money-back guarantee states its own conditions rather than implying them.
- No FDA warning letter, for the brand or for Renlo Health LLC.
- No pharmacy is named, and nothing says whether the medication is made to order or dispensed ready-made.
- No clinician is named — not a prescriber, not a medical director, not an advisory panel.
- Its comparison table shows unnamed rivals charging more at higher doses, with no source.
Show 4 more
- "Proven treatments" sits in a header shared with NAD+ and glutathione, whose evidence is nothing like the GLP-1s'.
- Its NAD+ and glutathione products carry a one-line benefit claim each and no trial reference.
- No street address, state or governing law is published — a company name in a copyright line is the whole disclosure.
- The crossed-out prices beside the real ones are never explained.
Verdict
The bottom line
On the question this site exists to ask — does what they claim match what the trials found — Renlo is the cleanest of the eight sellers we added this month. It cites correctly, labels honestly, and stops. What it will not tell you is who makes your medication or which doctor writes the prescription, and those are the two questions we would put to them before ordering.
Opens www.renlohealth.com. A link is not a recommendation to take anything.
One line, done right
Under Renlo's semaglutide chart:
"Average results in the STEP 1 trial, New England Journal of Medicine."
Under the tirzepatide chart:
"Average results in the SURMOUNT-1 trial, New England Journal of Medicine."
Right trial. Right journal. Right molecule on the right page. And the word average, which is what a trial mean is.
That should be unremarkable. It isn't. Of the eight sellers we added this month, one publishes five statistics under a heading reading "clinical data" and sources none of them, and another names these same two trials and then places their results roughly a year early.
Full analysis — 3 more sectionsWhat it doesn't do · The caveat that applies to everyone here · The unsourced claim is about money
What it doesn't do
Renlo publishes no timeline. No "month 3: established", no "month 6: 15%", no maintenance percentage.
That's where sellers usually come unstuck. STEP 1 reported its roughly 15% mean at 68 weeks 1 and SURMOUNT-1 its roughly 20% at 72 weeks 2. Turn either into a month-by-month curve and you have invented data. Renlo cites the average and stops.
The caveat that applies to everyone here
STEP 1 and SURMOUNT-1 tested the manufacturers' approved semaglutide and tirzepatide. Renlo sells compounded versions — made to order by a pharmacy, not FDA-approved, and never compared head to head with the approved product in any trial.
That isn't a criticism of Renlo specifically; it's true of nearly every seller on this site. It does mean the trial figures describe the molecule, not the particular preparation you'd receive.
The unsourced claim is about money
The one place Renlo asserts something it can't support is commercial:
"Most GLP-1 providers · Typical dose-based pricing CLIMBS · $200 starting dose / $270 mid dose / $330 higher dose"
No provider named, no source. Its own footnote calls this illustrative of typical pricing in the category, which is at least a hedge — but a table with nobody in it can't be checked by anyone.
Dose-based pricing is genuinely common, and Renlo's alternative to it is real: the same price at every dose, badged as a price lock, and consistent with everything else on the page.
Questions
Frequently asked questions
Are Renlo's weight-loss figures trustworthy?
They're attributed properly, which is the main thing. Each chart names the trial and the journal, puts the right trial on the right drug's page, and calls the number an average rather than a promise. There's no timeline attached, so nothing has been reshaped into a schedule the trials didn't support.
Do those trials apply to compounded medication?
Only in part, and this is true of nearly every seller we review. STEP 1 and SURMOUNT-1 tested the manufacturers' approved products, not compounded versions made to order by a pharmacy. Nothing published compares the two, so the trial figures describe the molecule rather than the exact preparation you'd be sent.
What about the NAD+ and glutathione products?
They carry a benefit line each — energy and cellular recovery, antioxidant support — and no trial reference. We haven't graded them here, because grading a claim against a page we haven't read is how a false verdict ships. Treat the trial citations on this site as covering the two GLP-1 products only.
Who makes the medication?
Renlo doesn't say. No pharmacy is named anywhere on the site, and nothing says whether the medication is made to order under your prescription or dispensed ready-made. No doctor is named either, which is the other question we'd want answered before ordering.
Is the LegitScript certification real?
Yes, and it belongs to this site rather than being borrowed. The certificate image loads for renlohealth.com and an invented certificate number returns an error in the same check. What it proves is that a certificate was issued to this domain — not that anything in the box has been tested.
Glossary
Key terms
Show definitions
- STEP 1
- The phase 3 trial of once-weekly semaglutide 2.4 mg for weight loss — 1,961 adults over 68 weeks, published in the New England Journal of Medicine in 2021.
- SURMOUNT-1
- The phase 3 trial of once-weekly tirzepatide for weight loss — 2,539 adults over 72 weeks at 5, 10 and 15 mg, published in the New England Journal of Medicine in 2022.
- Compounded
- Made to order by a pharmacy for an individual patient rather than manufactured and approved as a finished product. Compounded drugs are not FDA-approved and the FDA has not evaluated their safety, effectiveness or quality.
Compare
Others selling what Renlo Health sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Renlo Health's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 adults over 68 weeks, mean weight reduction of about 15%. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 adults over 72 weeks at 5, 10 and 15 mg once weekly. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.